Project Grant R44AG085775
Award Date
9/30/24
Completion Date
8/31/25
Dollars Obligated
$2.4M
Federal Agency
National Institute on Aging
Awardee
Virogenics, Inc. (UFJ8JM4CXU22)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,189,298 to Virogenics, Inc., a biotechnology company in San Diego, to conduct long-term non-clinical toxicology studies to support advancing the drug candidate CMS121 to Phase 2 clinical trials for the treatment of Alzheimer's disease (AD). The funding will support a 6-month rat study and a 9-month dog study to evaluate the safety of long-term daily administration of CMS121, which has...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC provides $994,436.00 in funding to develop novel brain-penetrant drugs for therapeutic targeting of Alzheimer's disease. The research aims to investigate the role of the histone methyltransferase G9A in Alzheimer's disease pathogenesis and the mechanism of action for a brain-penetrant G9A-targeted drug, MS1262, which has shown potential to restore cognitive and affective functions...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of small-molecule degraders of the amyloid precursor protein (APP) as potential first-in-class drugs for Alzheimer's disease (AD) therapy. The total award amount is $499,883 and the award period runs from September 1, 2024 to August 31, 2025. The key products and services to be delivered under this grant include: Optimization of lead APP degrader compounds through...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,968 to Hager Biosciences, LLC to further develop small molecule inhibitors of the Kv1.3 potassium channel as potential therapeutics for Alzheimer's disease. The key objectives are to: 1) complete in vitro characterization and initial pharmaceutical profiling of lead compound analogs; 2) initiate iterative lead optimization to improve potency and drug-like properties; and...
The Project Grant award R43AG085863 was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to support the development of a novel Alzheimer's disease therapeutic. The $504,732 award will enable Aphios Corp, a minority-owned biotechnology company, to nanoencapsulate an anti-CCR5 drug and evaluate its impact on brain inflammation and Alzheimer's disease in in vitro models and animal studies. The project aims to select promising...
This $514,862 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of an on-chip functional assay to identify candidate microtubule-binding drugs for treating Alzheimer's Disease and related dementias (ADRDs). The award recipient, Neuroindx, a for-profit, woman-owned small business, will create an in vitro platform that replicates key features of the neuronal microtubule microenvironment. This on-chip assay will use generated...
The National Institute on Aging (NIA) awarded a $500,000 project grant (CFDA 93.866 - Aging Research) to Alzarrok Bio LLC to develop a multi-target peptide drug for Alzheimer's disease (AD). The project aims to demonstrate the in vivo efficacy of the ALZ100 peptide, which has shown the ability to inhibit four key mediators of AD pathogenesis: amyloid-beta oligomers/fibrils, RAGE, TLR4, and S100A9. The goal is to show that ALZ100 can inhibit neuroinflammation and neurodegeneration in an AD...
The National Institute on Aging (NIA), under the Federal Grant Program CFDA 93.866 - Aging Research, awarded a $1,041,646 Project Grant to Cenna Biosciences Inc. to conduct early clinical development of a novel peptide drug candidate, modified P8 (MP8), for the treatment of Alzheimer's disease. The project aims to complete IND-enabling studies, engage in pre-IND discussions with the FDA, and initiate a Phase 1 clinical trial to evaluate the safety and tolerability of MP8. The grant will...
This $1,044,855 Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund Nemalife Inc. to deliver high-throughput testing of anti-aging and FDA-approved drugs in genetically diverse invertebrate Alzheimer's disease models. Under the Aging Research program (CFDA 93.866), the awardee will screen 300 anti-aging compounds and 200 FDA drugs to identify candidates that improve neuronal aging and protect against protein misfolding diseases...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $472,695 to 3D Bioanalytix, Inc., a woman-owned small business located in San Diego, CA, to develop a blood-based diagnostic test for detecting neurodegenerative diseases such as Alzheimer's and Parkinson's. The project aims to utilize a novel Covalent Protein Painting (CPP) technology platform to identify and differentiate the misfolded protein aggregates that characterize these...